Forensic Analysis · Technology / Software · as of Aug 7, 2026

Amphenol Corp /De/ (APH)

A forensic read on Amphenol Corp /De/ built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.

A · High-quality compounder

Forensic grade

Safe

Financial health

14.1

Distress distance

Clean

Earnings quality

Forensic signals

41.1

P / E (ttm)

31.8%

ROE

$208.6B

Market cap

0.59%

Dividend yield

51.7%

Revenue growth

This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.

Amphenol Corp /De/ earns an A (High-quality compounder) forensic quality grade, and its balance-sheet distress test reads 14.1, placing it in the Safe zone. 2 forensic signals were flagged in its latest SEC filings, led by accruals ratio (% of noa).

What the filings flag

+28.5%

FY2024→FY2025

Accruals ratio (% of NOA). Net operating assets grew +28.5% relative to their own average in FY2025 — scaled by NOA itself, not total assets (see the Forensic Screens card's differently-scaled Sloan Accrual Ratio for that read). Accruals are building sharply, and much of it is accounted for. The build is led by receivables up +43% against revenue +52% and inventory up +35% against +45% in cost of sales. That build tracks a +52% revenue year: net operating assets grew +33% and receivables +43%, so the balance sheet is carrying more volume rather than getting heavier per dollar of sales — the accrual build is funding demand the company is shipping, not earnings running ahead of collection. The cash-flow cross-check is more mixed: reported earnings ran behind operating cash by 7% of net operating assets, diverging from the balance-sheet accrual read.

+0.9%/yr

FY2022–FY2025

Share count. Diluted share count changed +3% over the last 3 years to FY2025 (+0.9%/yr). Roughly flat — buybacks ($665M) are about offsetting stock comp ($135M), not shrinking the count. Per-share value isn't being meaningfully helped or hurt by the count.

Key fundamentals

Latest Revenue$23.09B

Revenue Growth YoY+51.7%

Revenue CAGR (3yr)+22.3%

Net Margin18.5%

Free Cash Flow$4.38B

Return on Equity31.8%

Debt / Equity1.16x

The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Amphenol Corp /De/'s actual 10-K/10-Q/8-K filings?

Generate the AI investment read →

No credit card · informational only, not investment advice · see the track record

← Browse all forensic stock analyses

Data from SEC EDGAR public filings · metrics as of Aug 7, 2026. Forensic signals flag probability, not certainty.